Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN
NCT00002517Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 1993
- Primary completion
- May 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
Phase 3, randomised trial of idarubicin and mitoxantrone in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Complete Remission Rate and Duration of Complete Remission up to 5 years. Started Mar 1993; status: completed.
02
Drugs
idarubicinmitoxantrone
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00002517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002517.